VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
German biotechnology company Lophius Biosciences GmbH has announced that Dr Robert Phelps has joined the company as director of business operations. 16 December 2013
New York-based pharmaceutical company Forest Laboratories (NYSE: FRX) has announced new appointments to its executive leadership team. The appointments are part of Forest’s plans to broaden the organization as part of Project Rejuvenate. 16 December 2013
Danish pharmaceutical company H. Lundbeck A/S has appointed Jacob Tolstrup as head of the HR department following the resignation of former HR vice president Teddy Hebo Larsen. 16 December 2013
Israel’s Teva Pharmaceutical Industries announced yesterday that the vice chairman of its board of directors, Moshe Many, has requested to leave his position effective January 1, 2014. Prof Many will remain a member of Teva's Board. 11 December 2013
Swiss drug major Roche (ROG: SIX) has issued a list of members of the Board of Directors to be elected at its AGM on March 4, 2014. The board proposes Christoph Franz to be elected as Chairman of the Board. 10 December 2013
Denmark-based small molecule lead discovery company Nuevolution A/S has appointed Ton Berkien as Chief Business Officer from January 1. 9 December 2013
Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR: BR) has announced that Désiré Collen has decided to retire as chairman and board member. 9 December 2013
The France-based biotechnology company Novasep has announced Nadege Laborde as the new president of its industrial biotech business unit. 6 December 2013
The UK’s ‘Golden Triangle’ of biotech innovation can compete on the world stage, AstraZeneca (LSE: AZN) chief executive Pascal Soriot told the Financial Times Global Pharmaceutical & Biotechnology Conference in London today. 3 December 2013
Japan’s largest drugmaker, Takeda Pharmaceutical, says that Christophe Weber has been approved at the company's board of directors meeting to become chief operating officer and candidate as the next chief executive of the company. 29 November 2013
US-based MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca (LSE: AZN), has named Yong-Jun Liu as the company’s new head of research. 20 November 2013
UK-based biotech company Immunocore has appointed Jonathan Knowles as the new executive chairman of the board of directors with immediate effect. 20 November 2013
UK-based developer of inhaled therapies Vectura Group (LSE: VEC) has announced the appointment of Bruno Angelici to the board as an independent non-executive director and non-executive chairman designate. 20 November 2013
US-headquartered biotech company AmpliPhi BioSciences (OTCBB: APHB) has appointed Baxter Phillips III to the newly created position of vice president, corporate strategy and business development. 20 November 2013
To support its ongoing success as a BioPharma leader, US drug major Bristol-Myers Squibb says it is evolving its business model, creating a global integrated commercial organization and expanding the scope of its finance organization, and has announced a series of related changes within its senior management team. 14 November 2013